Effects of Metformin on Prostatic Tissue of Rats with Metabolic Syndrome and Benign Prostatic Hyperplasia.

Congyun Xu,Yan Xu,Zhou Shen,Hangcheng Zhou,Jun Xiao,Tao Huang

DOI: https://doi.org/10.1007/s11255-018-1826-9

IF: 2.2662

2018-01-01

International Urology and Nephrology

Abstract:To investigate the efficacy of insulin sensitizer on prostatic tissue in animal model with benign prostatic hyperplasia (BPH) secondary to metabolic syndrome (MetS).

What problem does this paper attempt to address?

Figure S1 from Metformin Inhibits Prostate Cancer Progression by Targeting Tumor-Associated Inflammatory Infiltration

Qiuli Liu,Dali Tong,Gaolei Liu,Jie Gao,Lin-ang Wang,Jing Xu,Xingxia Yang,Qiubo Xie,Yi Huang,Jinhui Pang,Luofu Wang,Yong He,Dianzheng Zhang,Qiang Ma,Weihua Lan,Jun Jiang

DOI: https://doi.org/10.1158/1078-0432.22470438.v1

2023-01-01

Abstract:Supplementary Figure S1. The effect of metformin on the expression of KI67, AR and neuroendocrine markers (Syn and CD56). Prostate tissues from TRAMP mice in both Control (Con) and Metformin (MET) groups at week 12, 25 and 37 were stained for KI67 (A, Magnifications: 40Ã-), AR (B, Magnifications: 20Ã-) as well as Syn and CD56 (C, Magnifications: 4Ã- for the images and 40Ã- at the lower right corner). * p < 0.05.
Metformin Inhibits Prostate Cancer Progression by Targeting Tumor-Associated Inflammatory Infiltration

Qiuli Liu,Dali Tong,Gaolei Liu,Jie Gao,Lin-ang Wang,Jing Xu,Xingxia Yang,Qiubo Xie,Yiqiang Huang,Jian Pang,Luofu Wang,Yong He,Dianzheng Zhang,Qiang Ma,Weihua Lan,Jun Jiang

DOI: https://doi.org/10.1158/1078-0432.ccr-18-0420

IF: 13.801

2018-01-01

Clinical Cancer Research

Abstract:Abstract Purpose: Inflammatory infiltration plays important roles in both carcinogenesis and metastasis. We are interested in understanding the inhibitory mechanism of metformin on tumor-associated inflammation in prostate cancer. Experimental Design: By using a transgenic adenocarcinoma of the mouse prostate (TRAMP) mouse model, in vitro macrophage migration assays, and patient samples, we examined the effect of metformin on tumor-associated inflammation during the initiation and after androgen deprivation therapy of prostate cancer. Results: Treating TRAMP mice with metformin delays prostate cancer progression from low-grade prostatic intraepithelial neoplasia to high-grade PIN, undifferentiated to well-differentiated, and PIN to adenocarcinoma with concurrent inhibition of inflammatory infiltration evidenced by reduced recruitment of macrophages. Furthermore, metformin is capable of inhibiting the following processes: inflammatory infiltration after androgen deprivation therapy (ADT) induced by surgically castration in mice, bicalutamide treatment in patients, and hormone deprivation in LNCaP cells. Mechanistically, metformin represses inflammatory infiltration by downregulating both COX2 and PGE2 in tumor cells. Conclusions: Metformin is capable of repressing prostate cancer progression by inhibiting infiltration of tumor-associated macrophages, especially those induced by ADT, by inhibiting the COX2/PGE2 axis, suggesting that a combination of ADT with metformin could be a more efficient therapeutic strategy for prostate cancer treatment. Clin Cancer Res; 24(22); 5622–34. ©2018 AACR.
Figure S2 from Metformin Inhibits Prostate Cancer Progression by Targeting Tumor-Associated Inflammatory Infiltration

Qiuli Liu,Dali Tong,Gaolei Liu,Jie Gao,Lin-ang Wang,Jing Xu,Xingxia Yang,Qiubo Xie,Yiqiang Huang,Jian Pang,Luofu Wang,Yong He,Dianzheng Zhang,Qiang Ma,Weihua Lan,Jun Jiang

DOI: https://doi.org/10.1158/1078-0432.22470435

2023-01-01

Abstract:Supplementary Figure S2. The effects of metformin on prostate stroma cells. (A) The ratio of epithelial cells to stroma cells in the mice at week 12, 25 and 37. (B) WPMY-1 cells were seeded in 96-well plates with 0.5Ã-105 cells per well in growth media with or without metformin (20mM). Cell viabilities were estimated by CCK8 every other day. (C and D) WPMY-1 cells were treated with different concentrations of metformin and the numbers of cells at different stages of the cycle were analyzed by ï¬,ow cytometry (C), or stained with PI and FITC-labelled Annexin V and subsequently underwent ï¬,ow cytometry analysis to determine the percentage of apoptotic cells (D).
Transcriptomic and Proteomic Analysis of Potential Therapeutic Target Genes in the Liver of Metformin‑treated Sprague‑Dawley Rats with Type 2 Diabetes Mellitus

Yitao Chen,Yangsheng Wu,Yuanxiao Yang,Zhiwei Xu,Junfeng Tong,Zheming Li,Xiaojie Zhou,Changyu Li

DOI: https://doi.org/10.3892/ijmm.2018.3535

IF: 5.314

2018-01-01

International Journal of Molecular Medicine

Abstract:The main actions of metformin are as follows: To reduce hyperglycemia via the suppression of gluconeogenesis, improve glucose uptake and insulin sensitivity, and stimulate activation of adenosine monophosphate-activated protein kinase during the treatment of diabetes mellitus. It is well known that metformin acts via complex mechanisms, including multitarget and multipathway mechanisms; however, the multi-targeted antidiabetic genes of metformin remain obscure. The present study aimed to perform transcriptomic and proteomic analysis of potential therapeutic target genes in the liver of metformin-treated Sprague-Dawley rats with type 2 diabetes mellitus. The type 2 diabetes rat model was established using streptozotocin. Fasting blood glucose, hemoglobin A1c, serum insulin and biological parameters were subsequently measured. Differentially expressed genes (DEGs) and proteins were identified in the rat livers by expression profile analysis and isobaric tags for relative and absolute quantitation (iTRAQ). A 1.5-fold alteration in gene expression, as determined using chip-based expression profile analysis, and a 1.2-fold alteration in protein expression, as determined using iTRAQ, were considered physiologically significant benchmarks, which were used to identify DEGS in metformin-treated rats with type 2 diabetes mellitus. The DEGs were verified using quantitative polymerase chain reaction (qPCR) and western blot analysis. Numerous hepatic genes involved in various metabolic pathways were affected by metformin; in particular, genes associated with lipid metabolism were markedly affected. Expression profile analysis and iTRAQ analysis suggested that carboxylesterase 1C subunit (Ces1C) and cholesterol 7-hydroxylyase (Cyp7a1) may serve as important DEGs, which were validated by qPCR and western blot analysis. Ces1C and Cyp7a1 are the main enzymes in cholesterol metabolism, yet the result of western blotting was not consistent with qPCR. The present study demonstrated that metformin may affect the expression of numerous hepatic genes involved in metabolic pathways, particularly the lipid and cholesterol metabolic pathways. Ces1C and Cyp7a1 may be considered novel therapeutic target genes in the liver, which are involved in the antidiabetic effects of metformin.
Effect of Metformin on the Improvement of Prostate Cancer in Diabetic Rats

Kaijian Hou,Wansheng Ke,Jianping Xiong

DOI: https://doi.org/10.1177/2058739219858553

2019-01-01

European Journal of Inflammation

Abstract:This study was designed to investigate the effect of metformin on the improvement of prostate cancer in diabetic rats. A total of 20 Sprague Dawley (SD) rats were equally divided into control and intervention groups. The intervention group received intragastric metformin 200 mg/kg, while the control group was given intragastric drinking water for 4 weeks. Tumor volumes were compared, all tumor specimens underwent routine pathological examination, immunohistochemical detection of E-cadherin and N-cadherin, and western blot assay. The tumor volume of control and intervention group was 462.15 ± 45.67 and 23.46 ± 5.32 mm3, respectively. Hematoxylin and eosin (HE) staining showed partial visible glandular structure with deepened nuclear staining in the intervention group. Immunohistochemistry showed high expression (6.5 ± 0.28 vs 3.8 ± 0.26, P < 0.05) of E-cadherin and low expression (3.4 ± 0.12 vs 7.8 ± 0.34, P < 0.05) of N-cadherin in the intervention group. Western blot assay showed higher expression of E-cadherin, while low N-cadherin in the intervention group. Metformin can effectively alleviate lesion extent of prostate cancer and mechanism may be related to upregulation of E-cadherin and downregulation of N-cadherin expression.
Effect of metformin on the risk of prostate cancer in patients with type 2 diabetes by considering different confounding factors: a meta-analysis of observational studies.

Yongbo Wang,Xiaoxue Liu,Pengfei Yan,Juan Tang,Tong Chen,Yi Sun,Wei Zhou,Yongyi Bi,Zhi-Jiang Zhang

DOI: https://doi.org/10.1097/CEJ.0000000000000514

2020-01-01

European Journal of Cancer Prevention

Abstract:Preclinical studies have suggested the antitumorigenic properties of metformin on prostate cancer; results from epidemiological studies remain contradictory. We aim to investigate the evidence of metformin and the risk of prostate cancer. PubMed, Embase, Cochrane Library, and Web of Science databases were searched for eligible studies. Meta-analyses were carried out using the most fully adjusted hazard ratios and the corresponding 95% confidence intervals. Eighteen cohort studies and six case-control studies representing 2 009 504 male patients with type 2 diabetes mellitus were identified. The pooled HR of prostate cancer for metformin therapy was 0.97 (0.84-1.12) in case-control studies and 0.94 (0.79-1.12) in cohort studies, respectively. In cohort studies, we found that there was a modest association in studies with samples from Europe, but not in studies with samples from North America, Asia, and Oceania. In addition, metformin showed a slightly protective effect compared with sulfonylurea, but not insulin and other comparators. Meta-regression analyses found that obesity and prostate-specific antigen adjustment in statistical models may be the sources of heterogeneity. However, there were no significant differences in subgroups stratified by time-related biases, analytical approaches, types of risk estimates, study quality, publication year, and whether adjusted for smoking, alcohol abuse, hemoglobin A1c, diabetes duration, and other confounding factors. Our study showed that metformin therapy was not associated with the risk of prostate cancer in patients with type 2 diabetes mellitus. However, exploratory analyses suggest that metformin use may be protective in a certain subgroup of patients.
Effects of metformin on SIRT1 expression of renal tissues in type 2 diabetic rats

Dan YU,Shan-dong YE,Ye-qiong LI,Wen HU

DOI: https://doi.org/10.3969/j.issn.1001-1978.2018.05.007

2018-01-01

Abstract:Aim To observe the effects of metformin (MET) on the silencing regulatory protein 1 (SIRT1) mRNA and protein expression in renal tissues of type 2 diabetic mellitus (T2DM) rats, and explore its reno-protective mechanisms. Methods Thirty model T2DM rats were randomly divided to glibenclamide in-tervention group (GLY group, 5 mg·kg-1·d-1), metformin intervention group (MET group,300 mg· kg-1· d-1) and diabetic control group (T2DM group),and 10 rats with normal glucose tolerance were used as normal control(NC group). After 8 weeks, HbA1c,blood glucose (BG), urea nitrogen (BUN), urinary albumin, creatinine and glomerular basement membrane thickness (GBMT) were detected. The ex-pression of SIRT1 protein in renal tissues was detected by immunohistochemistry, the expression of SIRT1 mRNA in renal tissues was detected by real-time PCR, and urinary SIRT1 protein was detected by ELISA. Results At the end of 8 weeks, the levels of BG,HbA1c,urinary albumin/urinary creatinine(UACR), urinary SIRT1/urinary creatinine (USIR) and GBMT in MET and GLY groups were significantly lower than those in T2DM group (P&lt;0.05). There was no sig-nificant difference in BG, HbA1c and GBMT between MET group and GLY group (P&gt;0.05). The expres-sions of SIRT1 mRNA and protein in MET group were significantly lower than those in NC group (P &lt;0.05), but higher than those in T2DM group (P &lt;0.05). The UACR, expression of SIRT1of renal tis-sues in MET group was higher than that in GLY group (P&lt;0.05),but urinary SIRT1 protein was lower than that in GLY group (P &lt;0.05). Conclusion Met-formin can increase the expressions of SIRT1 in renal tissues of T2DM rats,which may be related to its renal protection.
Effect Of Metformin On Cancer Risk And Treatment Outcome Of Prostate Cancer: A Meta-Analysis Of Epidemiological Observational Studies

Hongliang Yu,Li Yin,Xuesong Jiang,Xiujin Sun,Jing Wu,Hao Tian,Xianshu Gao,Xia He

DOI: https://doi.org/10.1371/journal.pone.0116327

IF: 3.7

2014-01-01

PLoS ONE

Abstract:Background: Laboratory studies have shown the anti-tumor effect of metformin on prostate cancer. However, recent epidemiological studies have yielded inconclusive results.Methods: We searched PubMed database from the inception to May 30 2014 for studies which assessed the effect of metformin use on cancer risk of prostate cancer, biochemical recurrence (BCR) and all-cause mortality of patients with prostate cancer. The pooled results and 95% confidence intervals (CIs) were estimated by random-effect model.Results: Twenty-one studies were eligible according to the inclusion criteria. Based on the pooled results of available observational studies, metformin use was significantly associated with a decreased cancer risk (14 datasets, 963991 male subjects, odds ratio: 0.91, 95% CI: 0.85-0.97) and BCR (6 datasets, 2953 patients, hazard ratio: 0.81, 95% CI: 0.68-0.98) of prostate cancer. However, the association of metformin use with all-cause mortality of patients with prostate cancer was not significant (5 datasets, 9241 patients, hazard ratio: 0.86, 95% CI: 0.64-1.14).Conclusion: Results suggest that metformin use appears to be associated with a significant reduction in the cancer risk and BCR of prostate cancer, but not in all-cause mortality of patients with prostate cancer.
Insulin exacerbated high glucose-induced epithelial-mesenchymal transition in prostatic epithelial cells BPH-1 and prostate cancer cells PC-3 via MEK/ERK signaling pathway

Tingting Yang,Yi Zhou,Haiyan Wang,Shangxiu Chen,Mengli Shen,Yinlu Hu,Tao Wang,Junjie Liu,Zhenzhou Jiang,ZhongJian Wang,Xia Zhu,Sitong Qian,Xiaoxing Yin,Qian Lu

DOI: https://doi.org/10.1016/j.yexcr.2020.112145

IF: 4.145

2020-09-01

Experimental Cell Research

Abstract:<p>As two most common progressive diseases of aging, type 2 diabetes mellitus (T2DM) and benign prostatic hyperplasia (BPH) were all characterized by endocrine and metabolic disorders. Here, our clinical study showed that there were significant differences in fasting blood glucose (FBG), fasting insulin (FINS), insulin resistance index (HOMA-IR) and prostate volume (PV) between simple BPH patients and BPH complicated with T2DM patients. Further analysis showed that HOMA-IR was positively correlated with PV in BPH complicated with T2DM patients. The <em>in vitro</em> experiment results showed that high glucose (HG) promoted EMT process in a glucose-dependent manner in human prostate hyperplasia cells (BPH-1) and prostate cancer cells (PC-3), and this pathological process was exacerbated by co-culture with insulin. Mechanistically, insulin-induced exacerbation of EMT was depended on the activation of MEK/ERK signaling pathway, and we suggested that insulin and its analogs should be used very carefully for the clinical antihyperglycemic treatment of BPH complicated with T2DM patients.</p>

oncology,cell biology
Effects of Metformin on Testicular Spermatogenic Function in Obese Rats

Wenjie YAN,Yang MU,Jing YANG

DOI: https://doi.org/10.14188/j.1671-8852.2017.0232

2018-01-01

Abstract:Objective:To investigate the influence of metformin on spermatogenesis in obese rats.Methods:Wistar rats were randomly divided into three groups:the control group,high-fat diet group and Metformin group.They were fed for 8 weeks with standard chow,high-fat diet,or high-fat diet with metformin.We obtained and analyzed the weight,glucose and lipid metabolism.The influence of obesity on spermatogenesis were explored in terms of testicular weight,semen parameters,histological changes in testis,hormone levels and inflammatory response in serum and testis,etc.The protective effect of metformin was also investigated from the above aspects.Results:Compared with Control group and Metformin group,HFD group exhibited higher body weight.Meanwhile,FBG,fasting insulin,HOMA-IR and leptin were significantly higher in HFD group than in the control group,but the testicular weight and semen parameters were significantly lower.Testosterone level in testis and serum were greatly decreased in HFD group compared with other two groups,while levels of serum and testicular proinflammatory cytokines (TNF-α,IL-6) were elevated.Testicular histology revealed that the diameter of seminiferous tubules and the amount of spermatogenic cells in testicular tissue were greatly reduced in HFD group than that in control and metformin groups.Conclusion:Met can improve the testicular spermatogenic function in obese rats from several aspects,such as improving the glucose and lipid metabolism,decreasing the disorder of sex hormone secretion,and inhibiting inflammatory reaction of the body and the testis.
The Underlying Mechanism of Metabolic Syndrome on Benign Prostatic Hyperplasia and Prostate Volume.

Bo-Wen Xia,Si-Cong Zhao,Zong-Ping Chen,Chao Chen,Tian-Shu Liu,Fan Yang,Yong Yan

DOI: https://doi.org/10.1002/pros.23962

2020-01-01

The Prostate

Abstract:Objective To investigate the potential mechanism of the effect of metabolic syndrome (MetS) on prostate volume (PV) and the risk of benign prostatic hyperplasia (BPH)/lower urinary tract symptoms (LUTS) and the relationships of MetS and the major pathogenic factors of MetS with the clinical progression of BPH/LUTS in older Chinese men. Subjects and Methods We analyzed clinical data obtained from 506 ostensibly healthy men who underwent routine health check-ups and recruited 415 subjects from a group of previously studied men after 4 years. We evaluated the associations of major pathological factors of MetS, including insulin resistance, subclinical inflammatory state, and sex hormone changes, with PV, the risk of BPH and the clinical progression of BPH/LUTS by using multiple linear regression and logistic regression. Results After adjustment for age, insulin, HOMA (homeostatic model assessment) index, leptin, resistin, adiponectin, C-reactive protein, tumor necrosis factor-alpha (TNF-alpha), sex hormone-binding globulin, and testosterone levels were significantly associated with PV (all P < .05), and in the age-adjusted logistic regression model, positive associations of resistin and TNF-alpha with BPH/LUTS were found (OR, 1.662, P = .007 and OR, 1.044, P < .001, respectively). Predictors of BPH/LUTS clinical progression were significantly correlated with MetS and TNF-alpha. The group with higher TNF-alpha levels had a higher rate of newly diagnosed BPH (9.5% vs 19.1%, P = .006) and a greater increase in PV levels (0.61 +/- 0.08 vs 1.09 +/- 0.35 cm(3), P <.001) after 4 years. Conclusions MetS and its pathological factors were associated with an increased PV and an increased risk of BPH/LUTS that is more prone to clinical progression. TNF-alpha may serve as an early biological indicator to identify which patients with BPH/LUTS are at higher risk of unfavorable outcomes.
Metformin: A promising clinical therapeutical approach for BPH treatment via inhibiting dysregulated steroid hormones-induced prostatic epithelial cells proliferation

Tingting Yang,Jiayu Yuan,Yuting Peng,Jiale Pang,Zhen Qiu,Shangxiu Chen,Yuhan Huang,Zhenzhou Jiang,Yilin Fan,Junjie Liu,Tao Wang,Xueyan Zhou,Sitong Qian,Jinfang Song,Yi Xu,Qian Lu,Xiaoxing Yin

DOI: https://doi.org/10.1016/j.jpha.2023.08.012

IF: 14.026

2023-08-23

Journal of Pharmaceutical Analysis

Abstract:Highlight • Sex steroid hormone compositions were dysregulated in the serum and prostate of BPH patients • Metformin inhibited PEC proliferation of BPH rats and DHT-cultured BPH-1 cells • Metformin suppressed DHT/AR-induced the formation of YAP1-TEAD4 complex • YAP1-TEAD4 complex was involved in the anti-proliferative effect of metformin The occurrence of benign prostate hyperplasia (BPH) was related to disrupted sex steroid hormones, and metformin (Met) had a clinical response to sex steroid hormone-related gynaecological disease. However, whether Met exerts an antiproliferative effect on BPH via sex steroid hormones remains unclear. Here, our clinical study showed that along with prostatic epithelial cell (PEC) proliferation, sex steroid hormones were dysregulated in the serum and prostate of BPH patients. As the major contributor to dysregulated sex steroid hormones, elevated DHT had a significant positive relationship with the clinical characteristics of BPH patients. Activation of AMPK by Met restored dysregulated sex steroid hormone homeostasis and exerted antiproliferative effects against DHT-induced proliferation by inhibiting the formation of androgen receptor (AR)-mediated YAP1-TEAD4 heterodimers. Met's anti-proliferative effects were blocked by AMPK inhibitor or YAP1 overexpression in DHT-cultured BPH-1 cells. Our findings indicated that Met would be a promising clinical therapeutic approach for BPH by inhibiting dysregulated steroid hormone-induced PEC proliferation. Graphical abstract Target and molecular mechanism of Met improving sex steroid hormones-induced BPH. Met regained dysregulated sex steroid hormones homeostasis, and inhibited PECs proliferation induced by dysregulated sex steroid hormones in BPH, and the anti-proliferation effects of Met was resulted from the regulation effect of AR-mediated YAP1-TEAD4 complex. Download : Download high-res image (152KB) Download : Download full-size image

pharmacology & pharmacy
Figure S5 from Metformin Inhibits Prostate Cancer Progression by Targeting Tumor-Associated Inflammatory Infiltration

Qiuli Liu,Dali Tong,Gaolei Liu,Jie Gao,Lin-ang Wang,Jing Xu,Xingxia Yang,Qiubo Xie,Yiqiang Huang,Jian Pang,Luofu Wang,Yong He,Dianzheng Zhang,Qiang Ma,Weihua Lan,Jun Jiang

DOI: https://doi.org/10.1158/1078-0432.22470423.v1

2023-01-01

Abstract:Supplementary Figure S5. The direct effects of metformin on prostate cancer cells. (A and B) PC-3 and DU145 cells were seeded in 96-well plates with 0.5Ã-105 cells per well in growth media with or without metformin (20mM). Cell viabilities were estimated by MTT every other day. (C and D) PC-3 and DU145 cells were seeded in 96-well plates with 0.5Ã-105 cells per well in growth media with different concentrations of metformin (0, 1, 5, 10, and 20 mM) and cell viabilities were estimated by MTT at 48 h. (E-H) PC-3 and DU145 cells were treated with different concentrations of metformin and the numbers of cells at different stages of the cycle were analyzed by ï¬,ow cytometry (E and F), or stained with PI and FITC-labelled Annexin V and subsequently underwent ï¬,ow cytometry analysis to determine the percentage of apoptotic cells (G and H).
Simvastatin Improves Benign Prostatic Hyperplasia: Role of Peroxisome-Proliferator-Activated Receptor-γ and Classic WNT/β-Catenin Pathway.

Zhen Wang,Shu Yang,Yan Li,Yongying Zhou,Daoquan Liu,Jianmin Liu,Michael E. DiSanto,Xinhua Zhang

DOI: https://doi.org/10.3390/ijms24054911

IF: 5.6

2023-01-01

International Journal of Molecular Sciences

Abstract:Benign prostatic hyperplasia (BPH) is a common disease in elderly men with an uncertain etiology and mechanistic basis. Metabolic syndrome (MetS) is also a very common illness and is closely related to BPH. Simvastatin (SV) is one of the widely used statins for MetS. Peroxisome-proliferator-activated receptor gamma (PPARγ), crosstalking with the WNT/β-catenin pathway, plays important roles in MetS. Our current study aimed to examine SV-PPARγ-WNT/β-catenin signaling in the development of BPH. Human prostate tissues and cell lines plus a BPH rat model were utilized. Immunohistochemical, immunofluorescence, hematoxylin and eosin (H&E) and Masson’s trichrome staining, construction of a tissue microarray (TMA), ELISA, CCK-8 assay, qRT-PCR, flow cytometry, and Western blotting were also performed. PPARγ was expressed in both prostate stroma and epithelial compartments and downregulated in BPH tissues. Furthermore, SV dose-dependently triggered cell apoptosis and cell cycle arrest at the G0/G1 phase and attenuated tissue fibrosis and the epithelial–mesenchymal transition (EMT) process both in vitro and in vivo. SV also upregulated the PPARγ pathway, whose antagonist could reverse SV produced in the aforementioned biological process. Additionally, crosstalk between PPARγ and WNT/β-catenin signaling was demonstrated. Finally, correlation analysis with our TMA containing 104 BPH specimens showed that PPARγ was negatively related with prostate volume (PV) and free prostate-specific antigen (fPSA) and positively correlated with maximum urinary flow rate (Qmax). WNT-1 and β-catenin were positively related with International Prostate Symptom Score (IPSS) and nocturia, respectively. Our novel data demonstrate that SV could modulate cell proliferation, apoptosis, tissue fibrosis, and the EMT process in the prostate through crosstalk between PPARγ and WNT/β-catenin pathways.
Protective effect of metformin in CD1 mice placed on a high carbohydrate-high fat diet.

Min Hou,Natalie Venier,Linda Sugar,Mireia Musquera,Michael Pollak,Alex Kiss,Neil Fleshner,Laurence Klotz,Vasundara Venkateswaran

DOI: https://doi.org/10.1016/j.bbrc.2010.05.152

IF: 3.1

2010-01-01

Biochemical and Biophysical Research Communications

Abstract:A high carbohydrate–high fat (HC–HF) diet-associated with hyperinsulinemia has been previously reported to induce accelerated growth of prostate cancer in a xenograft model. High energy supply and insulin/insulin growth factor-1 axis are two of the mechanisms proposed. We hypothesize that metformin may have a protective effect against prostate cancer progression by affecting metabolisms associated with high energy intake. In the present study, animals were randomized into five groups, receiving a HC–HF diet with 50, 100, or 250mg/kg body weight (mg/kg) metformin in drinking water, a standard diet or HC–HF diet alone. Animals on the HC–HF diet developed obesity and insulin resistance. They had significantly higher body weight, fasting blood glucose at an upper level of normal range, higher insulin secretion and utilization, and fatty degeneration of the liver. Metformin at the doses employed significantly reduced food and water consumption; however, only a dose of 250mg/kg showed a significant reduction in body weight gain and suppression of gluconeogenesis as well remarkably reduced insulin secretion. There was no observed metformin-related hepato-toxicity in any of the groups. In summary, metformin at various doses exhibits protective effects on the metabolic disorder caused by the HC–HF diet with the most effective protection at a dose of 250mg/kg. These effects may explain its translational role relating to its anti-neoplastic potential.
The Association Between Metabolic Syndrome And Benign Prostatic Hyperplasia: A Systematic Review And Meta-Analysis

Jinze Li,Lei Peng,Dehong Cao,Haocheng Gou,Yunxiang Li,Qiang Wei

DOI: https://doi.org/10.1080/13685538.2020.1771552

2021-01-01

Abstract:Objective:We performed this meta-analysis to assess the association between metabolic syndrome (MetS) and benign prostatic hyperplasia (BPH). Method:We conducted extensive searches on the PubMed, Science and Cochrane Library to identify all articles. Outcomes including annual prostate growth rate, prostate volume (PV), International Prostate Symptom Score (IPSS), IPSS sub-scores (voiding and storage), prostate- specific antigen (PSA), maximum urine flow rate (Qmax), post-void residual urine volume (PVR) and quality of life (QoL) were assessed. Results:21 studies with 15,317 patients were included. Patients with MetS had higher annual prostate growth rate [weighted mean difference (WMD) = 0.79;p < .001], larger PV (WMD = 2.62;p < .001), lower Qmax (WMD = -0.48;p = .001) and more PVR (WMD = 8.28;p < .001). However, no significant differences were found between two groups in IPSS (WMD = 0.20;p = .37), IPSS-voiding (WMD = -0.05;p = .78), IPSS-storage (WMD = -0.22;p = .26), PSA (WMD = 0.04;p = .43), and QoL (WMD = -0.01;p = .70). Conclusions:The study suggested that MetS may be one of the risk factors for the clinical progress of BPH. However, further study is warranted to support these results.
Metformin Sensitizes Prostate Cancer Cells to Radiation Through EGFR/p-DNA-PKCS in Vitro and in Vivo.

Tingting Zhang,Long Zhang,Tao Zhang,Jinhai Fan,Kaijie Wu,Zhenfeng Guan,Xinyang Wang,Lei Li,Jer-Tsong Hsieh,Dalin He,Peng Guo

DOI: https://doi.org/10.1667/rr13561.1

2014-01-01

Radiation Research

Abstract:Although neo-adjuvant radiotherapy is generally successful in treatment of advanced prostate cancer, radioresistance is still a major therapeutic problem in many patients. In the current study, we investigated the effects of metformin (1,1-dimethylbiguanide hydrochloride), a widely used antidiabetic drug, on tumor cell radiosensitivity in prostate cancer. Through clonogenic survival assays, we found that metformin treatment enhanced radiosensitivity of prostate cancer cells with a dose enhancement factor. Moreover, irradiation of subcutaneous C4-2 tumors in mice treated with metformin resulted in an increase in radiation-induced tumor growth delay (17.3 days to 29.5 days, P < 0.01), which indicates that the tumor radiosensitivity increased by metformin in vivo. We also measured the sublethal damage repair and analyzed double-strand breaks (DSBs) in X-irradiated cells. γ-H2AX, as an indicator of DSBs, had significantly more foci per cell in the group treated with metformin and radiation compared to groups treated with metformin or irradiation, respectively. Moreover, mice with subcutaneous tumor implants lived longer after a combined treatment of metformin and radiation. In addition, the reduced phosphorylation of DNA-PKcs caused by EGFR/PI3K/Akt down-regulation is essential for metformin to induce radiosensitivity in prostate cancer cells. Our results indicate that metformin enhances prostate cancer cell radiosensitivity in vitro and in vivo. Exposure to metformin before radiation therapy could be a beneficial option for the treatment of prostate cancer.
A Preliminary Study of the Impact of Insulin Resistance on the Growth of the Prostate in Patients with Benign Prostatic Hyperplasia

WANG Wei,HE Jia-yang,SHI Guo-wei,ZHOU Ren-yuan,WANG Wen-zhang,TU Min-qi,WANG Yang,FU Xu-chen,ZHANG Yue-hui

DOI: https://doi.org/10.3969/j.issn.1009-8291.2010.06.009

2010-01-01

Abstract:Objective To investigate the impact of insulin resistance on the prostate growth rate in patients with benign prostatic hyperplasia(BPH).Methods There were 139 BPH patients included in this preliminary study.The blood pressure,body weight and height were measured.Biochemical analyses including serum glucose,insulin,triglycerides,high-density lipoprotein cholesterol(HDL-C) and prostate-specific antigen(PSA) were performed.The prostate volume was measured by transrectal ultrasound and then annual prostatic growth rate was calculated.The patients were divided into two groups according to whether they were diagnosised to have insulin resistance.They were also divided into different groups in terms of metabolic syndrome and hyperinsulinemia,respectively.The data were analyzed by t test and analysis of variance.Results BPH patients with insulin resistance had significantly higher serum glucose,inlulin and annual prostate growth rate compared with those without insulin resistance.The median annual prostate growth rate was 0.29mL/year(P0.05).However,age,body mass index,systolic pressure,diastolic pressure,triglyceride,HDL-C,prostate volume and PSA levels had no significant difference between these two groups.Moreover,those with a higher serum insunlin level(serum insunlin 4.22mmol/L) had a higher prostate growth rate.In contrast,there was no significant difference in prostate growth rate between the patients with or without metabolic syndrome.Conclusions The present study demonstrates a further increase of prostate volume in BPH patients with insulin resistance.Thus,insulin resistance may contribute to development of BPH.It seems that BPH could be prevented by change of life style and medication for insulin resistance.Future studies are needed to confirm our results and to explain underlying mechanisms.
An Open-Label Pilot Study of Metformin As a Concomitant Therapy on Patients with Prostate Cancer Undergoing Androgen Deprivation Treatment

Wenhui Zhu,Hua Xu,Jing Ma,Jianming Guo,Wei Xue,Baojun Gu,Lu Sheng,Xudong Yao,Fukang Sun,Jian Gong,Weiliang Qiu,Qiang Ding,Haowen Jiang

DOI: https://doi.org/10.1159/000448691

2016-01-01

Urologia Internationalis

Abstract:Purpose: The study aimed to evaluate the effects of metformin on insulin, C-peptide and body weight in Chinese men undergoing androgen deprivation therapy (ADT). Methods: Between March 2013 and June 2014, 62 newly diagnosed patients of prostate cancer (PCa) due to receive ADT were recruited from 7 hospitals in Shanghai. Patients were randomized to respectively receive ADT (n = 31) and ADT + metformin (n = 31) for 6 months. Fasting and postprandial serum levels of insulin and C-peptide, blood glucose, prostate specific antigen, body mass index (BMI) and waist circumference (WC) were measured at the beginning and end of 6-month treatment. Results: Baseline characteristics were comparable between the 2 groups. Controlling for baseline levels, the ADT group had significantly higher levels of fasting glucose (p = 0.01) and higher WC (p = 0.04) than the ADT + metformin group. The levels of insulin, C-peptide and BMI did not differ significantly. Conclusions: Metformin may be potentially efficient as a concomitant therapy on patients with PCa undergoing androgen deprivation treatment.

Effects of Metformin on Prostatic Tissue of Rats with Metabolic Syndrome and Benign Prostatic Hyperplasia.

Figure S1 from Metformin Inhibits Prostate Cancer Progression by Targeting Tumor-Associated Inflammatory Infiltration

Metformin Inhibits Prostate Cancer Progression by Targeting Tumor-Associated Inflammatory Infiltration

Figure S2 from Metformin Inhibits Prostate Cancer Progression by Targeting Tumor-Associated Inflammatory Infiltration

Transcriptomic and Proteomic Analysis of Potential Therapeutic Target Genes in the Liver of Metformin‑treated Sprague‑Dawley Rats with Type 2 Diabetes Mellitus

Effect of Metformin on the Improvement of Prostate Cancer in Diabetic Rats

Effect of metformin on the risk of prostate cancer in patients with type 2 diabetes by considering different confounding factors: a meta-analysis of observational studies.

Effects of metformin on SIRT1 expression of renal tissues in type 2 diabetic rats

Effect Of Metformin On Cancer Risk And Treatment Outcome Of Prostate Cancer: A Meta-Analysis Of Epidemiological Observational Studies

Insulin exacerbated high glucose-induced epithelial-mesenchymal transition in prostatic epithelial cells BPH-1 and prostate cancer cells PC-3 via MEK/ERK signaling pathway

Effects of Metformin on Testicular Spermatogenic Function in Obese Rats

The Underlying Mechanism of Metabolic Syndrome on Benign Prostatic Hyperplasia and Prostate Volume.

Metformin: A promising clinical therapeutical approach for BPH treatment via inhibiting dysregulated steroid hormones-induced prostatic epithelial cells proliferation

Figure S5 from Metformin Inhibits Prostate Cancer Progression by Targeting Tumor-Associated Inflammatory Infiltration

Simvastatin Improves Benign Prostatic Hyperplasia: Role of Peroxisome-Proliferator-Activated Receptor-γ and Classic WNT/β-Catenin Pathway.

Protective effect of metformin in CD1 mice placed on a high carbohydrate-high fat diet.

The Association Between Metabolic Syndrome And Benign Prostatic Hyperplasia: A Systematic Review And Meta-Analysis

Metformin Sensitizes Prostate Cancer Cells to Radiation Through EGFR/p-DNA-PKCS in Vitro and in Vivo.

A Preliminary Study of the Impact of Insulin Resistance on the Growth of the Prostate in Patients with Benign Prostatic Hyperplasia

An Open-Label Pilot Study of Metformin As a Concomitant Therapy on Patients with Prostate Cancer Undergoing Androgen Deprivation Treatment